Evidence map›Paper›PMID 32504246›Full record

ArticleCancer immunology, immunotherapy : CII2020

Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8

Charlotte M Mousset, Willemijn Hobo, Aafke de Ligt, Sjoerd Baardman, Nicolaas P M Schaap, Joop H Jansen, Anniek B van der Waart, Harry Dolstra

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Charlotte M MoussetDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute of Molecular Life Sciences, Radboud university medical center, Geert Grooteplein Zuid 8, 6525 GA, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-6443-513X
Willemijn HoboDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute of Molecular Life Sciences, Radboud university medical center, Geert Grooteplein Zuid 8, 6525 GA, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-8206-8185
Aafke de LigtDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute of Molecular Life Sciences, Radboud university medical center, Geert Grooteplein Zuid 8, 6525 GA, Nijmegen, The Netherlands.
Sjoerd BaardmanDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute of Molecular Life Sciences, Radboud university medical center, Geert Grooteplein Zuid 8, 6525 GA, Nijmegen, The Netherlands.
Nicolaas P M SchaapDepartment of Hematology, Radboud university medical center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0001-7696-4752
Joop H JansenDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute of Molecular Life Sciences, Radboud university medical center, Geert Grooteplein Zuid 8, 6525 GA, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0001-9459-568X
Anniek B van der WaartDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute of Molecular Life Sciences, Radboud university medical center, Geert Grooteplein Zuid 8, 6525 GA, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0001-5986-3060
Harry DolstraDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute of Molecular Life Sciences, Radboud university medical center, Geert Grooteplein Zuid 8, 6525 GA, Nijmegen, The Netherlands. Harry.Dolstra@radboudumc.nl.ORCID http://orcid.org/0000-0002-3998-687X
Radboud University Nijmegen · NL

Funding

KWF Kankerbestrijding KUN2014-6716
6 · The paper itself

Abstract

AKT-inhibition is a promising approach to improve T cell therapies; however, its effect on CD4

Indexed as

BenzimidazolesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Culture TechniquesCell DifferentiationCells, CulturedHumansQuinoxalines1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-oneBenzimidazolesQuinoxalinesAKTMemoryPolyfunctionalityT cellTh1Th2

Identifiers

PMID32504246
PMCPMC7568704
OpenAlexW3033702853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.